belongs to a group of medicines known as vinca alkaloids. Vinca alkaloids are also called antimicrotubule agents because they affect microtubules, which are proteins within cells that help cells divide and multiply.
Marqibo works by binding to tubulin, a protein that makes up microtubules. When bound to tubulin, Marqibo alters the structure of microtubules, preventing them from functioning normally. As a result, the altered microtubules cannot help cells divide. This stops cells' growth and causes the cells to die.
Marqibo can kill both cancer cells and healthy cells, which is what causes many of the dangerous side effects. However, it has a greater effect on cells that rapidly multiply. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Marqibo treatment.
The active ingredient in Marqibo, vincristine
, is contained in tiny particles of fat (liposomes). This changes how the medication is processed in the body. Marqibo stays in the body longer than nonliposomal vincristine (Vincasar PFS®
). It is thought to be more effective than Vincasar PFS and to have fewer side effects.
Is It Safe for Children to Use Marqibo?
This medication is not approved for use in children, as it has not been adequately studied in this age group. Talk to your child’s healthcare provider about the risks and benefits of using Marqibo in children.
Marqibo has not been adequately studied in older adults, so it is unknown if they would respond to, or tolerate, the medicine any differently than younger age groups. Marqibo can be used in older adults; however, dosing in older adults should be done cautiously, as they may be more sensitive to the side effects of the medication.